​

Vera Therapeutics (VERA) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

VERA Stock Forecast

Vera Therapeutics (VERA) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $77.60, with a high of $97.00 and a low of $33.00. This represents a 63.33% increase from the last price of $47.51.

$15 $32 $49 $66 $83 $100 High: $97 Avg: $77.6 Low: $33 Last Closed Price: $47.51

VERA Stock Rating

Vera Therapeutics stock's rating consensus is Buy, based on 14 Wall Street analysts. The breakdown includes 1 Strong Buy (7.14%), 11 Buy (78.57%), 2 Hold (14.29%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 14 0 2 11 1 Strong Sell Sell Hold Buy Strong Buy

VERA Price Target Upside V Benchmarks

TypeNameUpside
StockVera Therapeutics63.33%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-56
Avg Price Target-$77.60$75.50
Last Closing Price$47.51$47.51$47.51
Upside/Downside-63.33%58.91%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 261102--13
Dec, 251112--14
Nov, 252102--14
Oct, 25292--13
Sep, 25292--13
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 19, 2025Goldman Sachs$95.00$47.6999.20%99.96%
Dec 11, 2025Laura ChicoWedbush$33.00$45.42-27.34%-30.54%
Dec 08, 2025Gavin Clark-GartnerEvercore ISI$97.00$45.79111.84%104.17%
Dec 05, 2025Pivotal Research$73.00$42.6171.32%53.65%
Nov 28, 2025H.C. Wainwright$90.00$33.33170.03%89.43%
Jun 03, 2025Greg HarrisonScotiabank$65.00$30.91110.29%36.81%
Mar 21, 2024Laura ChicoWedbush$34.00$42.87-20.69%-28.44%
Jan 26, 2024Ryan DeschnerRaymond James$37.00$30.1822.60%-22.12%
Dec 18, 2023Ryan DeschnerRaymond James$29.00$15.8483.08%-38.96%
Jan 04, 2023Jefferies$6.00$6.37-5.81%-87.37%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 19, 2025Goldman SachsBuyBuyhold
Dec 19, 2025Bank of America SecuritiesBuyBuyhold
Dec 11, 2025WedbushNeutralNeutralhold
Dec 08, 2025Evercore ISIOutperformOutperformhold
Dec 05, 2025Cowen & Co.BuyBuyhold
Nov 28, 2025H.C. WainwrightBuyBuyhold
Nov 26, 2025Cantor FitzgeraldOverweightOverweighthold
Sep 18, 2025Cantor FitzgeraldOverweightOverweighthold
Aug 04, 2025Wolfe ResearchOutperformPeer Performdowngrade
Jun 03, 2025ScotiabankOutperformOutperformhold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.25$-2.75----
Avg Forecast$-2.18$-2.83$-3.15$-3.04$-2.07$0.86
High Forecast$-2.11$-2.65$-2.23$-2.06$-0.09$0.86
Low Forecast$-2.26$-2.99$-4.73$-4.16$-3.80$0.86
Surprise %3.21%-2.83%----

Revenue Forecast

$0 $110M $220M $330M $440M $550M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.86M-----
Avg Forecast$1.86M$1.86M$1.86M$42.58M$210.59M$516.01M
High Forecast$1.86M$1.86M$1.86M$42.58M$210.59M$516.01M
Low Forecast$1.86M$1.86M$1.86M$42.58M$210.59M$516.01M
Surprise %------

Net Income Forecast

$-250M $-190M $-130M $-70M $-10M $50M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-95.99M$-152.15M----
Avg Forecast$-95.99M$-120.50M$-148.70M$-133.00M$-154.25M$36.57M
High Forecast$-90.22M$-113.19M$-95.27M$-88.17M$-4.04M$36.57M
Low Forecast$-96.57M$-127.81M$-202.13M$-177.82M$-162.30M$36.57M
Surprise %-26.26%----

VERA Forecast FAQ

Is Vera Therapeutics stock a buy?

Vera Therapeutics stock has a consensus rating of Buy, based on 14 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 11 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Vera Therapeutics is a favorable investment for most analysts.

What is Vera Therapeutics's price target?

Vera Therapeutics's price target, set by 14 Wall Street analysts, averages $77.6 over the next 12 months. The price target range spans from $33 at the low end to $97 at the high end, suggesting a potential 63.33% change from the previous closing price of $47.51.

How does Vera Therapeutics stock forecast compare to its benchmarks?

Vera Therapeutics's stock forecast shows a 63.33% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Vera Therapeutics over the past three months?

  • January 2026: 7.69% Strong Buy, 76.92% Buy, 15.38% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 7.14% Strong Buy, 78.57% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 14.29% Strong Buy, 71.43% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.

What is Vera Therapeutics’s EPS forecast?

Vera Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.15, marking a 14.55% increase from the reported $-2.75 in 2024. Estimates for the following years are $-3.04 in 2026, $-2.07 in 2027, and $0.86 in 2028.

What is Vera Therapeutics’s revenue forecast?

Vera Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $1.86M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $42.58M, followed by $210.59M for 2027, and $516.01M for 2028.

What is Vera Therapeutics’s net income forecast?

Vera Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-149M, representing a -2.26% decrease from the reported $-152M in 2024. Projections indicate $-133M in 2026, $-154M in 2027, and $36.57M in 2028.